Karyopharm Therapeutics Inc.

Clinical research in myelofibrosis includes both JAK inhibitor-naïve and previously treated populations, with attention to moderate thrombocytopenia and treatment-naïve disease. The sponsor also studies combinations involving ruxolitinib in this hematologic setting.

• JAK inhibitor-naïve myelofibrosis
• Previously treated myelofibrosis
• Treatment-naïve myelofibrosis
• Moderate thrombocytopenia

The research focus centers on disease control in chronic marrow-related disorders and symptom burden associated with myelofibrosis.